期刊文献+

甲状腺转移性肾透明细胞癌1例报道并文献复习 被引量:1

Renal clear cell carcinoma thyroid metastasis:a case report and literature review
下载PDF
导出
摘要 目的探讨甲状腺转移性肾透明细胞癌(clear cell renal carcinoma,CCRC)的临床病理学特征。方法结合文献复习,对1例甲状腺转移性肾透明细胞癌的组织病理学、免疫组织化学特点进行分析。结果本例患者为72岁老年女性,发现甲状腺肿物1月入院。彩超检查示:双侧甲状腺结节。大体:肿瘤切面灰黄色,质中,包膜完整。镜下:肿瘤细胞呈圆形,胞浆透亮,核小而圆,排列呈巢状和腺泡状,间质纤维组织较少,有血窦散在。免疫表型:瘤细胞主要表达CD10,CK(L),EMA,Vimentin,Ki-67增殖指数约5%。结论甲状腺转移性CCRC为一种较少见的肿瘤,患者通常起病隐匿,易误诊,需通过病理组织学观察及免疫组织化学标记为其正确诊断提供可靠方法。 Objective To investigate the clinicopathological features of renal clear cell carcinoma (CCRC) metastatic to thyroid gland. Methods A thyroid metastasis from renal clear cell carcinoma case was analyzed using histopathology and immunohistochemistry combined with literature review. Results The patient was a 72-year-old female with thyroid nodule identified for a month. Color Doppler ultrasonography examination showed bilateral thyroid nodules. Gross pathologic examination revealed grayish yellow tumor in complete capsule with medium texture. Histologic examination indicated tumor cells with clear cytoplasm, small and round nucleus, nested and acinar growth pattern, few interstitial fibrous tissue, and scattered sinusoid-like vascularity. Immunohistochemistry examination showed tumor cells were CD10, CK (L), EMA and vimentin positive with 5% of Ki-67 proliferation index. Conclusion CCRC thyroid metastasis is a rare tumor with which patients usually have concealed symptoms and are misdiagnosed easily. Combination of histopathology and immunohistochemistry provide a reliable method for a correct diagnosis.
出处 《中国组织化学与细胞化学杂志》 CAS CSCD 2017年第5期506-509,共4页 Chinese Journal of Histochemistry and Cytochemistry
关键词 甲状腺 肾透明细胞癌 转移 病理学 Thyroid gland renal clear cell carcinoma metastasis pathology
  • 相关文献

参考文献7

二级参考文献54

  • 1杨举伦,蔡琳,冯毓正,邹红,罗学林.6例透明细胞肉瘤的临床病理及免疫组化观察[J].临床与实验病理学杂志,1994,10(4):307-308. 被引量:4
  • 2沈宏,施源,高佩嘉.12例透明细胞汗腺瘤临床病理学观察[J].诊断病理学杂志,1995,2(3):140-141. 被引量:4
  • 3Wilhelm S,Carter C,Lynch M,et al.Discovery and development of sorafenib:a multikinase inhibitor for treating cancer[J].Nat Rev Drug Discov,2006,5 (10):835-844.
  • 4Cortes J,Rousselot P,Kim D W,et al.Dasatinib induces complete hematologic and cytogenetic responses in patientswith imatinib-resistant orintolerant chronic myeloid leukemia in blast crisis[J].Blood,2007,109(8):3207-3213.
  • 5Hochhaus A,Kantarjian H M,Baccarani M,et al.Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy[J].BIood,2007,109(6):2303-2309.
  • 6Traxler P,Allegrini P R,Brandt R,et al.AEE788:a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor recep tor tyrosine kinase inhibitorwith antitumor and antiangiogenic activity[J].Cancer Res,2004,64 (14):4931-4941.
  • 7Liu Y,Poon R T,Li Q,et al.Both antiangiogenesis and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584[J].Cancer Res,2005,65(9):3691-3699.
  • 8Strumberg D,Schultheis B,Adamietz I A,et al.Phase I dose escalation study of telatinib (BAY 5729352) in patients with advanced solid tumours[J].Br J Cancer,2008,99 (10):1579-1585.
  • 9Nikolinakos P,Heymach J V.The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies[J].J Thorac Oncol,2008,3(6):131-134.
  • 10Osawa M,Takigawa N,Kiura K,et al.Isolated metastasis of lung cancer to the thyroid gland.Lung Cancer,2007,58:156-158.

共引文献55

同被引文献11

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部